PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsVenetoclax
Venclexta, Venclyxto(venetoclax)
Venclexta, Venclyxto (venetoclax) is a small molecule pharmaceutical. Venetoclax was first approved as Venclexta on 2016-04-11. It is used to treat lymphoid leukemia and myeloid leukemia acute in the USA. It has been approved in Europe to treat b-cell chronic lymphocytic leukemia. The pharmaceutical is active against apoptosis regulator Bcl-2. In addition, it is known to target bcl-2-like protein 1, bcl-2-like protein 2, and induced myeloid leukemia cell differentiation protein Mcl-1.
Download report
Favorite
Case Study: Multiple Myeloma
Top 200 Pharmaceuticals by Retail Sales
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
hemic and lymphatic diseasesD006425
immune system diseasesD007154
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Venclexta
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Venetoclax
Tradename
Company
Number
Date
Products
VENCLEXTAAbbVieN-208573 RX2016-04-11
3 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
venclextaNew Drug Application2024-07-12
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
lymphoid leukemia—D007945C91
Agency Specific
FDA
EMA
Expiration
Code
VENETOCLAX, VENCLEXTA, ABBVIE
2026-05-15ODE-239
2025-11-21ODE-211
2025-06-08ODE-185
Patent Expiration
Patent
Expires
Flag
FDA Information
Venetoclax, Venclexta, Abbvie
95392512033-09-06U-2538
109939422033-09-06U-3114
111100872033-09-06U-3222, U-3223
114132822033-09-06U-3412
115901282033-09-06U-3548
113695992032-05-23DP
87226572032-01-29DP
107308732031-11-21DP
85463992031-06-27DS, DP
91749822030-05-26U-2323, U-2445, U-2446, U-2537
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01X: Other antineoplastic agents in atc
— L01XX: Other antineoplastic agents in atc
— L01XX52: Venetoclax
HCPCS
No data
Clinical
Clinical Trials
671 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LeukemiaD007938—C9516622343362424
Myeloid leukemia acuteD015470—C92.013815425244306
Myeloid leukemiaD007951—C9211713020240264
Lymphoid leukemiaD007945—C91468421120149
B-cell chronic lymphocytic leukemiaD015451—C91.1326522217126
Heart failureD006333HP_0001635I50———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LymphomaD008223—C85.969788—3130
Myelodysplastic syndromesD009190—D4656472—382
PreleukemiaD011289——46342—163
Non-hodgkin lymphomaD008228—C85.940231—253
Precursor cell lymphoblastic leukemia-lymphomaD054198——22332—852
SyndromeD013577——35311——50
NeoplasmsD009369—C8028214—447
Mantle-cell lymphomaD020522——15252—136
Large b-cell lymphoma diffuseD016403—C83.322141—231
B-cell lymphomaD016393——22131—230
Show 7 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
RecurrenceD012008——2230——140
Myelomonocytic leukemia chronicD015477—C93.12121——130
Myelomonocytic leukemia juvenileD054429—C93.32120——129
Hematologic neoplasmsD019337——2014——326
Follicular lymphomaD008224—C821412——121
Myeloproliferative disordersD009196—D47.199——116
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_0000340—39——212
Precursor t-cell lymphoblastic leukemia-lymphomaD054218——311———12
B-cell lymphoma marginal zoneD018442—C88.486———12
Myelomonocytic leukemia acuteD015479—C92.569———10
Show 49 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
CarcinomaD002277—C80.04————4
Prostatic neoplasmsD011471—C613————3
Castration-resistant prostatic neoplasmsD064129——2————2
Hodgkin diseaseD006689—C811———12
Myeloid sarcomaD023981—C92.32————2
Non-small-cell lung carcinomaD002289——2————2
AggressionD000374EFO_0003015—2————2
T-cell lymphoma cutaneousD016410——1———12
Gata2 deficiencyD000077428—D46.222————2
Pancreatic neoplasmsD010190EFO_0003860C251————1
Show 16 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
FrailtyD000073496—R53.1————11
Plasma cell leukemiaD007952—C90.1————11
Congenital abnormalitiesD000013EFO_0003915Q89.9————11
Eye abnormalitiesD005124HP_0000478Q15.9————11
Chromosome aberrationsD002869Orphanet_68335—————11
Chromosome disordersD025063EFO_0003831Q99.9————11
Cardiac arrhythmiasD001145EFO_0004269I49.9————11
Sudden death cardiacD016757EFO_0004278—————11
DeathD003643PATO_0001422—————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameVenetoclax
INNvenetoclax
Description
Venetoclax is a member of the class of pyrrolopyridines that is a potent inhibitor of the antiapoptotic protein B-cell lymphoma 2. It is used for treamtment of chronic lymphocytic leukemia with 17p deletion. It has a role as an apoptosis inducer, an antineoplastic agent and a B-cell lymphoma 2 inhibitor. It is a member of oxanes, a N-sulfonylcarboxamide, an aromatic ether, a pyrrolopyridine, a member of monochlorobenzenes, a N-arylpiperazine, a N-alkylpiperazine and a C-nitro compound.
Classification
Small molecule
Drug classbcl-2 (B-cell lymphoma 2) inhibitors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1
Identifiers
PDB—
CAS-ID1257044-40-8
RxCUI—
ChEMBL IDCHEMBL3137309
ChEBI ID—
PubChem CID49846579
DrugBankDB11581
UNII IDN54AIC43PW (ChemIDplus, GSRS)
Target
Agency Approved
BCL2
BCL2
Organism
Homo sapiens
Gene name
BCL2
Gene synonyms
NCBI Gene ID
Protein name
apoptosis regulator Bcl-2
Protein synonyms
B-cell CLL/lymphoma 2, protein phosphatase 1, regulatory subunit 50
Uniprot ID
Mouse ortholog
Bcl2 (12043)
apoptosis regulator Bcl-2 (Q4VBF6)
Alternate
BCL2L1
BCL2L1
BCL2L2
BCL2L2
MCL1
MCL1
Organism
Homo sapiens
Gene name
BCL2L1
Gene synonyms
BCL2L, BCLX
NCBI Gene ID
Protein name
bcl-2-like protein 1
Protein synonyms
Apoptosis regulator Bcl-X, protein phosphatase 1, regulatory subunit 52
Uniprot ID
Mouse ortholog
Bcl2l1 (12048)
bcl-2-like protein 1 (Q64373)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Venclexta – AbbVie
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 11,318 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
43,979 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use